Research chemicalResearch chemicalBenzodiazepine analogueDepressant

Zapizolam

Also known as Zapizolam

Written by enwyReviewed 4 Aug 20261 sources0 comments

Zapizolam is a triazolobenzodiazepine designer drug related to alprazolam, sold as a research chemical. It produces sedation, anxiolysis and amnesia and is reported to be potent by weight. It has no clinical human characterisation; information is limited to analytical detection and user reports.

01 Overview

Zapizolam is a triazolobenzodiazepine, a structural class that includes alprazolam and the various -zolam designer benzodiazepines. It appeared on the research-chemical market and has been detected in seized products. It is typically encountered as powder, pellets or blotters and is potent per milligram.

Reported effects are those of a fast-onset triazolobenzodiazepine: anxiolysis, sedation, muscle relaxation and amnesia. As with related -zolam compounds, blackouts and disinhibition at higher doses, along with rapid development of dependence, are the main practical hazards. No clinical human data exist.

02 Mechanism

Positive allosteric modulation of GABA-A receptors at the benzodiazepine site; the triazole ring confers high potency and fast onset.

03 Dosing

Tier	Dose	Route	Notes
Light	0.2–0.5 mg	Oral	Potent; volumetric dosing advised.
Common	0.5–1 mg	Oral	Fast onset encourages redosing and over-sedation.

04 Effects

Effect	Magnitude	Evidence
AnxiolysisRapid reduction of anxiety typical of triazolobenzodiazepines.	Marked	Anecdotal
SedationDrowsiness and reduced arousal.	Strong	Anecdotal
DisinhibitionImpulsivity and reduced judgement at higher doses.		Anecdotal

05 Side effects

Effect	Severity	Frequency	Evidence
Dependence and withdrawalRapid tolerance and dependence; abrupt cessation risks seizures.	Severe	Common with regular use	Anecdotal
Blackouts and amnesiaBlackouts, amnesia and disinhibited behaviour, worsened by alcohol.	Moderate	Common at higher doses	Anecdotal
Additive respiratory depressionDangerous with opioids or alcohol.	Life-threatening	With CNS depressants	Observational

06 Legal status

United States

Not federally scheduled

as of Jan 2026

Controlled substance

as of Jan 2026

07 References

Detection of zapizolam in NPS productsDrug Testing and Analysis

08 Discussion0 comments

Create account

Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.

This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.